Literature DB >> 2572626

Demonstration of the cell cycle positions of taxol-induced "asters" and "bundles" by sequential measurements of tubulin immunofluorescence, DNA content, and autoradiographic labeling of taxol-sensitive and -resistant cells.

J R Roberts1, E K Rowinsky, R C Donehower, J Robertson, D C Allison.   

Abstract

We used reliable and relatively inexpensive equipment to make sequential sets of measurements of antitubulin immunofluorescence, Feulgen staining, and autoradiography on the same cells. This was done to evaluate tubulin conformations, DNA content, and [3H]-thymidine incorporation in cell lines sensitive (HL60) and resistant (K562) to the novel anti-tubulin chemotherapeutic agent taxol. Numbers of cells with microtubule bundles have been found to correlate with sensitivity to taxol by clonogenic assay for several leukemic cell lines. We have found that cells with "asters" produced by taxol exposure are in mitosis and that cells with taxol-induced "bundles" are in G0/G1, S, and G2 phases. We further found that S-phase cells with microtubule bundles in both sensitive (HL60) and resistant (K562) cell lines were able to incorporate [3H]-thymidine after 4-hr exposure to taxol. As microtubule bundles and asters occur in cells of the same cell cycle phases in both lines, we conclude that the greater frequency of cells with microtubule bundles reported for sensitive cells after taxol treatment cannot result from drug exclusion nor from different effects of the drug on cell microtubules in these two leukemic lines.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2572626     DOI: 10.1177/37.11.2572626

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  8 in total

1.  Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine.

Authors:  E K Rowinsky; M J Citardi; D A Noe; R C Donehower
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

Review 2.  Risks and benefits of taxanes in breast and ovarian cancer.

Authors:  L B Michaud; V Valero; G Hortobagyi
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

3.  Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat.

Authors:  S J Sollott; L Cheng; R R Pauly; G M Jenkins; R E Monticone; M Kuzuya; J P Froehlich; M T Crow; E G Lakatta; E K Rowinsky
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

Review 4.  Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.

Authors:  C M Spencer; D Faulds
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

5.  Passive mechanical behavior of human neutrophils: effects of colchicine and paclitaxel.

Authors:  M A Tsai; R E Waugh; P C Keng
Journal:  Biophys J       Date:  1998-06       Impact factor: 4.033

Review 6.  Taxol®: The First Microtubule Stabilizing Agent.

Authors:  Chia-Ping Huang Yang; Susan Band Horwitz
Journal:  Int J Mol Sci       Date:  2017-08-09       Impact factor: 5.923

7.  Taxol crystals can masquerade as stabilized microtubules.

Authors:  Margit Foss; Buck W L Wilcox; G Bradley Alsop; Dahong Zhang
Journal:  PLoS One       Date:  2008-01-23       Impact factor: 3.240

8.  S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells.

Authors:  C Hennequin; N Giocanti; V Favaudon
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.